Work

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

Year: 2016

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-016-0374-3

Authors: Lee S. Rosen, Patricia LoRusso, Wen Wee Ma, Jonathan W. Goldman, Amy Weise, A. Dimitrios Colevas, Alex Adjei, Salim Yazji, Angela Shen, Stuart Johnston, Hsin-Ju Hsieh, Iris T. Chan, Branimir I. Sikic

Institutions: University of California, Los Angeles, Yale University, Roswell Park Comprehensive Cancer Center, The Barbara Ann Karmanos Cancer Institute, Stanford University, Exelixis (United States), Arvinas (United States), Nektar Therapeutics (United States), Genentech

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Baxalta, Exelixis, Genentech, National Cancer Institute

Award: CANCER CENTER SUPPORT GRANT

OpenAlex ID: W2474527756

FWCI: 4.214

Cites: 38

Cited by: 86

Related to: 10